Results 141 to 150 of about 5,019 (231)

Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy. [PDF]

Cancer Immunol Res, 2022
You R, Artichoker J, Ray A, Gonzalez Velozo H, Rock DA, Conner KP, Krummel MF.   +6 more
europepmc   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy. [PDF]

Signal Transduct Target Ther
Mu M, Li H, Chen B, Fan R, Zhong K, Wang G, Feng C, Chen N, Guo G, Tong A, Zou B.   +10 more
europepmc   +1 more source

Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model. [PDF]

FASEB J, 2023
Yang J, Jiao J, Draheim KM, Yang G, Yang H, Yao LC, Shultz LD, Greiner DL, Rajagopal D, Vessillier S, Maier CC, Mohanan S, Cai D, Cheng M, Brehm MA, Keck JG.   +15 more
europepmc   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. [PDF]

Nat Commun
Huang Y, Liu S, Zhang X, Zhang B, Shi F, Zhang J, Shao S, Han H, Ma X, Xie J, Zhang J, Yu H, Zhao Y, Jin J, Xu D, Liu L, Wang J, Tan Y, Xu K, Jin L, Du Q, Geng Y, Liu A, Xu W.   +23 more
europepmc   +1 more source

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab. [PDF]

Leuk Lymphoma, 2023
Parisi R, Cowen EA, Gu S, Dusza S, Pulitzer M, Geyer MB, King AC, Markova A.   +7 more
europepmc   +1 more source

Recent Advances in Photocatalyst‐Driven Protein Labeling and Proximity Mapping

The Chemical Record, Volume 26, Issue 8, August 2026.
Photocatalyst‐driven protein labeling and proximity mapping have rapidly advanced as powerful strategies for spatiotemporal control in complex biological environments. This review integrates recent developments across single‐electron transfer and energy transfer‐based mechanisms and highlights how catalyst design, reactive intermediates, and diffusion ...
Shinichi Sato, Kazuki Miura, Juki Nakao, Hiroyuki Nakamura   +3 more
wiley   +1 more source

Erratum: Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. [PDF]

Theranostics
Zhong L, Shi W, Gan L, Liu X, Huo Y, Wu P, Zhang Z, Wu T, Peng H, Huang Y, Zhao Y, Yuan Y, Deng Z, Tang H.   +13 more
europepmc   +1 more source

Integrin α5β1 in pancreatic cancer: A stromal vulnerability rather than a stand‐alone oncogenic driver

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Xin He, Taoying Huang, Meiqi Xin, Chengsheng Wu   +3 more
wiley   +1 more source